

# Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

## Recombinant Anti-Src (phospho Y419) antibody [EPR17734]

RRID:AB\_2924399

Type: Antibody

---

### Proper Citation

Abcam Cat# ab185617, RRID:AB\_2924399

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2924399](http://antibodyregistry.org/AB_2924399)

**Proper Citation:** Abcam Cat# ab185617, RRID:AB\_2924399

**Target Antigen:** Src (phospho Y419)

**Host Organism:** rabbit

**Clonality:** recombinant monoclonal

**Comments:** Applications: Flow Cyt (Intra), WB, Dot blot

**Antibody Name:** Recombinant Anti-Src (phospho Y419) antibody [EPR17734]

**Description:** This recombinant monoclonal targets Src (phospho Y419)

**Target Organism:** rat, mouse, human

**Clone ID:** EPR17734

**Antibody ID:** AB\_2924399

**Vendor:** Abcam

**Catalog Number:** ab185617

**Record Creation Time:** 20231110T031321+0000

**Record Last Update:** 20260829T203218+0000

---

### Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-Src (phospho Y419) antibody [EPR17734].

No alerts have been found for Recombinant Anti-Src (phospho Y419) antibody [EPR17734].

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Yu J, et al. (2025) FMNL2/SRC-mediated androgen receptor translocation into the nucleus promotes enzalutamide resistance of prostate cancer. iScience, 28(4), 112205.

Toh SY, et al. (2024) Therapeutic application of extracellular vesicular EGFR isoform D as a co-drug to target squamous cell cancers with tyrosine kinase inhibitors. Developmental cell, 59(16), 2189.